

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 JUN 01 CAS REGISTRY Source of Registration (SR) searching  
enhanced on STN  
NEWS 4 JUN 26 NUTRACEUT and PHARMAML no longer updated  
NEWS 5 JUN 29 IMSCOPROFILE now reloaded monthly  
NEWS 6 JUN 29 EFFULL adds Simultaneous Left and Right Truncation  
(SLART) to AB, MCLM, and TI fields  
NEWS 7 JUL 09 PATDPAFULL adds Simultaneous Left and Right  
Truncation (SLART) to AB, CLM, MCLM, and TI fields  
NEWS 8 JUL 14 USGENE enhances coverage of patent sequence location  
(PSL) data  
NEWS 9 JUL 27 CA/CAPLUS enhanced with new citing references  
NEWS 10 JUL 16 GBFULL adds patent backfile data to 1855  
NEWS 11 JUL 21 USGENE adds bibliographic and sequence information  
NEWS 12 JUL 28 EFFULL adds first-page images and applicant-cited  
references  
NEWS 13 JUL 28 INPADOCDB and INPAFAMDB add Russian legal status data  
NEWS 14 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 15 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 16 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 17 AUG 24 CA/CAPLUS enhanced with legal status information for  
U.S. patents  
NEWS 18 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 19 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:06:05 ON 23 SEP 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:06:26 ON 23 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 22 SEP 2009 HIGHEST RN 1186072-05-8  
DICTIONARY FILE UPDATES: 22 SEP 2009 HIGHEST RN 1186072-05-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10531783-broad.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Me,Et,n-Pr,i-Pr

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:06:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6241 TO ITERATE

32.0% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 120083 TO 129557

PROJECTED ANSWERS: 38 TO 460

L2 4 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:06:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 126827 TO ITERATE

100.0% PROCESSED 126827 ITERATIONS  
SEARCH TIME: 00.00.03

248 ANSWERS

L3 248 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

186.36

186.58

FILE 'CAPLUS' ENTERED AT 16:07:33 ON 23 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2009 VOL 151 ISS 13

FILE LAST UPDATED: 22 Sep 2009 (20090922/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 13

L4 127 L3

=> s 14 py not > 2003

MISSING OPERATOR L4 PY

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s 14 not py > 2003

7813375 PY > 2003

L5 82 L4 NOT PY > 2003

=> s 15 and ligand

374492 LIGAND

L6 0 L5 AND LIGAND

```

=> s 15 and affinity
    335097 AFFINITY
L7      1 L5 AND AFFINITY

=> s 15 and support
    579048 SUPPORT
L8      0 L5 AND SUPPORT

=> s 15 and solid
    1221171 SOLID
L9      2 L5 AND SOLID

=> s 15 and Fab
    19564 FAB
L10     0 L5 AND FAB

=> s 15 and IgG
    86381 IGG
L11     0 L5 AND IGG

=> s 15 and human
    2261058 HUMAN
L12     2 L5 AND HUMAN

=> s 15 and chromatography
    358201 CHROMATOGRAPHY
L13     0 L5 AND CHROMATOGRAPHY

=> s 15 and column
    470328 COLUMN
L14     0 L5 AND COLUMN

=> s 15 and matrix
    622387 MATRIX
L15     0 L5 AND MATRIX

=> s 15 and immunology
    6097 IMMUNOLOGY
L16     0 L5 AND IMMUNOLOGY

=> s 17 or 19 or 112
L17     5 L7 OR L9 OR L12

```

```

=> d 117 ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

```


```

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS ON STN
ACCESSION NUMBER:      2002:449646 CAPLUS
DOCUMENT NUMBER:       137:33211
TITLE:                 Preparation of N-indolylurea derivatives as peroxisome
                        proliferator activated receptor  $\delta$  (PPAR  $\delta$ )
                        activators
INVENTOR(S):           Takahashi, Toshihiro; Sakuma, Shogo; Endo, Tsuyoshi;
                        Tendo, Atsushi; Yoshida, Shinichi; Kobayashi, Kunio;
                        Mochiduki, Nobutaka; Yamakawa, Tomio; Kanda, Takashi;
                        Masui, Seiichiro
PATENT ASSIGNEE(S):    Nippon Chemiphar Co., Ltd., Japan
SOURCE:                PCT Int. Appl., 81 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              Japanese
FAMILY ACC. NUM. COUNT: 1

```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046154	A1	20020613	WO 2001-JP10576	20011204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002024138	A	20020618	AU 2002-24138	20011204
PRIORITY APPLN. INFO.:			JP 2000-369890	A 20001205
			WO 2001-JP10576	W 20011204
OTHER SOURCE(S):		MARPAT 137:33211		
GI				




AB Urea derivs. represented by the general formula (I) or salts thereof [wherein Y = O, S; n = an integer of 0-4; R<sub>4</sub>, R<sub>5</sub> = H, C1-8 alkyl optionally substituted by 1-3 of halogen atoms; W = CO<sub>2</sub>H, C2-8 alkoxy, carbonyl, SO<sub>3</sub>H, cyano, tetrazolyl; a solid line accompanied by a dotted line represents a single or double bond; one of R<sub>a</sub>, R<sub>b</sub>, and R<sub>c</sub> is R<sub>1</sub>N(R<sub>2</sub>)CON(R<sub>3</sub>)X and the other two groups are H, C1-8 alkyl, C6-10 aryl, C1-8 alkyl-C6-10 aryl; wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = H, C1-8 alkyl optionally substituted by 1-3 of halogen atoms, C1-8 alkoxy-C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-8 alkyl, C6-10 aryl, C6-10 aryl-C1-8 alkyl, heterocyclyl, heterocyclyl-C1-8 alkyl; X = C1-8 alkylene, remaining two R<sub>8</sub> and R<sub>9</sub> are each hydrogen or C1-8 alkyl; aryl, heterocyclyl, or aryl or heterocyclyl of arylalkyl or heterocyclylalkyl group is optionally substituted in R<sub>a</sub>, R<sub>b</sub>, and R<sub>c</sub>] are prepared. These compds. are useful as blood sugar-lowering agents, hypolipidemics, antiobesity agents, hypocholesteremics, antiarteriosclerotics, anticancer agents, antiinflammatory agents, etc. Thus, 47 mg 2-[1-[2-(N'-2,4-dichlorophenyl isocyanate) was added to a solution of 78 mg 2-[[1-[2-(isobutylamino)ethyl]indol-5-yl]oxy]-2-methylpropionic acid Et ester in EtOAc and stirred at room temperature for 0.5 h to give 83% 2-[[1-[2-(N'-2,4-dichlorophenyl-N-isobutylamino)ethyl]indol-5-yl]oxy]-2-methylpropionic acid Et ester which (96 mg) was dissolved in ethanol, treated with 1 M aqueous NaOH, stirred at room temperature for 16 h, treated with 0.1 M aqueous HCl under ice-cooling, and stirred at room temperature for 1 h to give 100% 2-[[1-[2-(N'-2,4-dichlorophenyl-N-isobutylureido)ethyl]indol-5-yl]oxy]-2-methylpropionic acid (II). In an assay for activating effect of PPARδ receptor using CV-1 cells transfected with PPARδ receptor-expressing plasmid, luciferase-expressing plasmid, and β-galactosidase-expressing plasmid, II at 10<sup>-5</sup> M exhibited 106% activation compared to L-165041.

IT 435277-48-BP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

RN 435277-48-8 CAPLUS

CN Propanoic acid, 2-[[[1-[2-[[[(2,4-dichlorophenyl)methylamino]carbonyl](2-methylpropyl)amino]ethyl]-1H-indol-5-yl]oxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:175776 CAPLUS

TITLE: Identification of a novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template

AUTHOR(S): Aslanian, Robert; Mutahi, Mwangi W.; Shih, Neng-Yang; McCormick, Kevin D.; Piwinski, John J.; Ting, Pauline C.; Albanese, Margaret M.; Berlin, Michael Y.; Zhu, Xiaohong; Wong, Shing-Chun; Rosenblum, Stuart B.; Jiang, Yueheng; West, Robert; She, Susan; Williams, Shirley M.; Bryant, Matthew; Hey, John A.

CORPORATE SOURCE: The Schering Plough Research Institute, Kenilworth,  
NJ. 07033, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002),  
12(6), 937-941

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 137:279130

GI




AB A novel series of histamine H3 receptor antagonists, based on the 4-benzyl-(1H-imidazole-4-yl) template, incorporating urea and carbamate linkers has been prepared. The urea I is a selective H3 antagonist and demonstrates excellent oral plasma levels in the rat and monkey.

IT 466671-37-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of imidazolymethylbenzylureas as histamine H3 receptor antagonists)  
 RN 466671-37-4 CAPLUS  
 CN Urea, N-(3,5-dichlorophenyl)-N,N'-dimethyl-N'-[[4-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]phenyl]methyl]- (CA INDEX NAME)



IT 705264-28-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of imidazolymethylbenzylureas as histamine H3 receptor antagonists)  
 RN 705264-28-4 CAPLUS  
 CN Urea, N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-5-ylmethyl)phenyl]methyl]-N,N'-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)  
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:237842 CAPLUS  
 DOCUMENT NUMBER: 134:266205  
 TITLE: Preparation of collagen formation-inhibiting benzene derivatives  
 INVENTOR(S): Kojima, Hiroshi; Sakamoto, Makoto; Yasumura, Koichi  
 PATENT ASSIGNEE(S): Ohtsuka Pharmaceutical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 97 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089412	A	20010403	JP 1999-269015	19990922

## OTHER SOURCE(S):

MARPAT 134:266205

AB (R1)aC6H5-aVBWA [I; R1 = H, halo, OH, NO2, cyano, etc.; a = 1-5; V = NHCO, CONH, NHCONH, NHC(S)NH, SCH2CONH, etc.; B = p-C6H4, (un)substituted pyridine-2,5-diyl, pyrimidine-2,5-diyl, pyrazine-2,5-diyl, pyridine-2,3-diyl; W = O, S, SO, NH, CO, CH2, SO2; A = aryl] or their salts, useful for treatment of lung or liver fibrosis, are prepared 3,4,5-Trimethoxybenzoic acid (440 mg) was amidated by 500 mg 3-amino-6-(4-tert-butylphenoxy)pyridine in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.HCl and 1-hydroxybenzotriazole in DMF at room temperature for 1 day to give 750 mg I [(R1)a = 3,4,5-(OMe)3, V = CONH, B = pyridine-2,5-diyl, W = O, A = C6H4CMe3-p]. I [(R1)a = 3,4-Cl2, V = CONH, B = p-C6H4, W = O, A = 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl] in vitro inhibited TGF  $\beta$ -1-induced collagen synthesis in human LI90 cells with IC50 of 2.37  $\mu$ M.


IT 332009-21-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of collagen formation-inhibiting benzene derivs.)


RN 332009-21-9 CAPLUS

CN Urea, N-(3,4-dichlorophenyl)-N'-[6-[(2,3-dihydro-1-oxo-1H-inden-4-yl)oxy]-3-pyridinyl]-N-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:66714 CAPLUS

DOCUMENT NUMBER: 128:136098

ORIGINAL REFERENCE NO.: 128:26594h,26595a

TITLE: A Novel Class of Orally Active Non-Peptide Bradykinin  
B2 Receptor Antagonists. 1. Construction of the Basic  
Framework

AUTHOR(S): Abe, Yoshito; Kayakiri, Hiroshi; Satoh, Shigeki;  
Inoue, Takayuki; Sawada, Yuki; Imai, Keisuke; Inamura,  
Noriaki; Asano, Masayuki; Hatori, Chie; Katayama,  
Akira; Oku, Teruo; Tanaka, Hirokazu

CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa  
Pharmaceutical Co., Ibaraki, 300-26, Japan

SOURCE: Journal of Medicinal Chemistry (1998), 41(4), 564-578  
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A novel class of potent, selective, and orally active non-peptide  
bradykinin (BK) B2 receptor antagonists were designed and synthesized  
starting from 8-benzoyloxymidazo[1,2-a]pyridine derivative(I). The unique  
screening lead I was discovered by a 2-step intentional random screening  
process, involving recognition of the relationship between BK and  
angiotensin II (Ang II) and the common structural features. Systematic  
chemical modification of I elucidated the structural requirements essential  
for B2 binding affinity leading to the identification of  
8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-  
methylimidazo[1,2-a]pyridine skeleton as the basic framework of this new  
series of B2 antagonists. A mol. modeling study suggested the key role of  
the N-methylanilide moiety at the 3-position of the 2,6-dichlorobenzene  
ring to allow these compds. to adopt the characteristic active  
conformation. The representative lead compds. inhibited the specific  
binding of [3H]BK to guinea pig ileum membrane preps. expressing B2  
receptors, with nanomolar IC50s and also displayed in vivo functional  
antagonistic activities against BK-induced bronchoconstriction in guinea  
pigs at an oral dose of 1 mg/kg. Pharmacokinetic studies of the  
N-butylamide and Et urea moieties at the 3-position of the  
2,6-dichlorobenzene in rats highlighted their excellent oral  
bioavailabilities, indicating that they represent the first orally active  
non-peptide B2 antagonists reported to date.

IT 160642-24-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and MSBAR of nonpeptide bradykinin B2 receptor antagonists)

RN 160642-24-0 CAPLUS

CN Urea, N-[3-[[3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]methyl]-2,4-  
dichlorophenyl]-N,N'-dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 69 THERE ARE 69 CAPLUS RECORDS THAT CITE THIS  
RECORD (70 CITINGS)  
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1967:508325 CAPLUS  
DOCUMENT NUMBER: 67:108325  
ORIGINAL REFERENCE NO.: 67:20403a,20406a  
TITLE: Tuberculostatic urea derivatives  
INVENTOR(S): Gagneux, Andre R.; Frick, Wilhelm  
PATENT ASSIGNEE(S): Geigy, J. R., A.-G.  
SOURCE: Ger., 5 pp.  
CODEN: GWXXAW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1246722		19670810	DE 1966-G48486	19661117
CH 456570			CH	
FR 1504098			FR	
FR 6433			FR	
GB 1125559			GB	
US 3539626		19701110	US	19681212
US 3621040		19710000	US	
US 3621100		19711116	US	19681118
			CH	19651118

PRIORITY APPLN. INFO.:

AB The title compds. are prepared by treating a) adamantylamines with an aryl isocyanate, aryl isothiocyanate, or a carbanilic or thiocarbanilic acid derivative; b) an adamantyl isocyanate, isothiocyanate, carbamate, or thiocarbamate with an aryl amine; or c) an adamantyl and aryl substituted carbodiimide with H2O or H2S. Thus, a mixture of 36.5 millimoles 1-adamantylamine in 100 ml. absolute C6H6 and 33.3 millimoles 3,4-dichlorophenyl isocyanate in 100 ml. absolute C6H6 is heated at 80° 1 hr. and cooled and the filtered solid stirred 1 hr. in 100 ml. N HCl to give 1-(1-adamantyl)-3-(3,4-dichlorophenyl)urea, m. 220-1°. Similarly prepared are the following substituted 1-(1-adamantyl)ureas (substituents and m.p. given): 3-(p-MeC6H4), 252-6°; 3-(p-ClC6H4), 242-3°; 3-(2,4-Cl2C6H3), 221-2°; 3-[6,3-Cl(F3C)C6H3], 233-4°; 3-(o-MeOC6H4), 234-6°; 3-(p-MeOC6H4), 235-8°; 3-[2,5(MeO)2C6H3], 240-2°; 3-(m-AcC6H4), 200-4°; 1-Me-3-(3,4-Cl2C6H3), 193-5°; 3-Me-3-(3,4-Cl2C6H3), 180-2°. Also prepared are

1-(1-adamantyl)thioureas: 3-(p-ClC<sub>6</sub>H<sub>4</sub>), 172-3°; 3-(2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>), 181-3°; 3-[4,3-Cl(F<sub>3</sub>C)C<sub>6</sub>H<sub>3</sub>], 169-71°; and 3-(3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>)

(I), 189-92°. Similarly prepared are 1-(1-adamantylmethyl)-3-(3,4-dichlorophenyl)urea, m. 189-91°;

1-( $\alpha$ -methyl-1-adamantylmethyl)-3-(3,4-dichlorophenyl)urea, m. 195-8°; 1-(tricyclo[4.3.1.1<sup>3,8</sup>]undec-3-yl)-3-(3,4-

dichlorophenyl)urea, m. 233-6°; and

1-(2-oxaadamant-1-yl)-3-(3,4-dichlorophenyl)urea, m. 208-10°. To a mixture of 15 millimoles I in 600 ml. absolute dioxane is added 50 millimoles anhydrous MgSO<sub>4</sub> and 120 millimoles PbO, the mixture stirred at 60° 15 hrs., cooled, and filtered, the filtrate taken to dryness in vacuo, the oily residue dissolved in 300 ml. pentane, the turbid solution filtered through C, and the filtrate concentrated to give

1-(1-adamantyl)-3-(3,4-dichlorophenyl)carbodiimide, m. 60-1°

(pentane). A mixture of 50 millimoles bicyclo[3.3.1]nonane-3,7-dione and 50 millimoles PhCH<sub>2</sub>NH<sub>2</sub> in 300 ml. tetrahydrofuran is refluxed 0.5 hr., cooled, and added with stirring to 100 millimoles LiAlH<sub>4</sub> in 100 ml. absolute Et<sub>2</sub>O, the mixture stirred at 40° 6 hrs., 19 ml. N NaOH added with

ice-cooling, the precipitate filtered off, the filtrate evaporated, the residue dissolved in 500 ml. Me<sub>2</sub>CO, and 5 ml. concentrated HCl added, to afford N-benzyl-2-oxaadamantylamine - HCl (II), m. 242-5°. A solution of 33 millimoles II in 100 ml. EtOH is hydrogenated with 50 atmospheric H in the presence of 2 g. 5% Pd-C at 100° 2 hrs., the mixture cooled and filtered, the filtrate evaporated, 25 ml. concentrated NaOH solution added to

the

residue, the mixture extracted with Et<sub>2</sub>O, the Et<sub>2</sub>O evaporated, and the residue sublimed at 60° and 0.1 mm. to yield 2-oxaadamantylamine, m. 148-54°; hydrochloride m. 280°.

IT 16192-94-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 16192-94-2 CAPLUS

CN Urea, N-(3,4-dichlorophenyl)-N-methyl-N'-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-  
(CA INDEX NAME)

